Failure of antiepileptic drugs in controlling seizures in epilepsy: What do we do next?

被引:4
|
作者
Galindo-Mendez, Brahyan [1 ]
Mayor, Luis C. [2 ]
Velandia-Hurtado, Fernando [1 ]
Calderon-Ospina, Carlos [1 ]
机构
[1] Univ Rosario, Sch Med & Hlth Sci, Dept Basic Sci, Bogota, Colombia
[2] Univ Los Andes, Hosp Univ Fdn Santa Bogot, Fac Med, Bogota, Colombia
来源
关键词
Epilepsy; Malformations of cortical development; Cortical dysplasia-focal epilepsy syndrome; Anticonvulsants; Drug resistance;
D O I
10.1016/j.ebcr.2015.03.004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Medically intractable epilepsy is a clinical condition of concern that arises when a patient with epilepsy suffers seizures, despite a trial of two or more antiepileptic drugs (AEDs) suitable for the type of epilepsy that are prescribed atmaximum tolerated doses, does not achieve control of seizures. This diagnosis could be related to cortical dysplasias. We report the case of a 5-year-old girl with a previous normal neurological development and no family history of epilepsy who presentedwith focal-type seizures at age 4. She started treatment by taking different AEDs for seizure control. She continued having frequent seizures that sometimes progressed to generalized seizures and status epilepticus. After a focal cortical resection performed in the area where interictal spikes were detected, the pathology confirmed a type IIb cortical dysplasia as the cause of the epilepsy. This article discusses cortical dysplasias as a cause of pharmacoresistant epilepsy and its treatment. (C) 2015 The Authors. Published by Elsevier Inc.
引用
收藏
页码:6 / 8
页数:3
相关论文
共 50 条
  • [21] What do we do next; To survive, grow and be distinguished
    Gunay, Yaylali
    CHINA FOUNDRY, 2010, 7 (04) : 412 - 418
  • [22] THERMAL SPRAY CHALLENGES: WHAT DO WE DO NEXT?
    Berndt, Christopher C.
    Ang, Andrew
    ADVANCED MATERIALS & PROCESSES, 2017, 175 (05): : 55 - 58
  • [23] What do we do next;To survive,grow and be distinguished
    Yaylali Günay
    China Foundry, 2010, 7 (04) : 412 - 418
  • [24] Pediatric disaster preparedness: What do we do next?
    Severin, Paul N.
    PEDIATRICS, 2006, 118 (05) : 2254 - 2255
  • [25] Thermal spray challenges: What do we do next?
    Berndt, Christopher C.
    Ang, Andrew
    Advanced Materials and Processes, 2017, 175 (05): : 55 - 58
  • [26] The bovine tuberculosis dilemma - What do we do next?
    Gallagher, J
    VETERINARY JOURNAL, 2000, 160 (02): : 85 - 86
  • [27] Consequences of epilepsy: Why do we treat seizures?
    Jones, MW
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1998, 25 (04) : S24 - S26
  • [28] Cannabinoids for epilepsy: What do we know and where do we go?
    Brodie, Martin J.
    Ben-Menachem, Elinor
    EPILEPSIA, 2018, 59 (02) : 291 - 296
  • [29] International haemovigilance: what have we learned and what do we need to do next?
    Wood, E. M.
    Ang, A. L.
    Bisht, A.
    Bolton-Maggs, P. H.
    Bokhorst, A. G.
    Flesland, O.
    Land, K.
    Wiersum-Osselton, J. C.
    Schipperus, M. R.
    Tiberghien, P.
    Whitaker, B. I.
    TRANSFUSION MEDICINE, 2019, 29 (04) : 221 - 230
  • [30] Adherence intervention research: What have we learned and what do we do next?
    Bender, B
    Milgrom, H
    Apter, A
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 112 (03) : 489 - 494